Anthony D. Elias, MD, on Triple-Negative Breast Cancer: Treatment Update

NCCN 2018 Annual Conference
Tweet this page

Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews promising experimental treatments, as well as PARP inhibitor therapy in TNBC, including the implications of newly approved olaparib for gBRCA-mutant breast cancer.

Jun

Today In Oncology

FDA Grants Priority Review to Expanded Use of Gardasil 9 in Women and Men Aged 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases

Statement From FDA Commissioner on Agency Efforts to Advance the Patient Voice in Medical Product Development and Regulatory Decision-Making

AMA Plans Advocacy Outreach to Expand Colorectal Screening

Ibrutinib in Relapsed or Refractory Follicular Lymphoma

Suboptimal Use of Initial Chemotherapy in Newly Diagnosed AML

;